Ultrasound reliably predicts success and failure of single-dose methotrexate treatment of ectopic pregnancy, according to research conducted at Boston Medical Center and presented Wednesday at the RSNA meeting.
Ultrasound reliably predicts success and failure of single-dose methotrexate treatment of ectopic pregnancy, according to research conducted at Boston Medical Center and presented Wednesday at the RSNA meeting.
Results from a retrospective trial of 62 patients, presented by BMC radiologist Dr. Sarah Bixby, indicate yolk sac and fetal heart motion predicted all 17 treatment failures. A yolk sac was identified in 15 of 17 of failed cases, producing a specificity and sensitivity of 88% and 100%, respectively. Fetal heart motion was observed in one patient who failed treatment and was not present in any successful cases.
Methotrexate has been a front-line treatment for ectopic pregnancy since 1992, but the success rate of the single-dose methotrexate therapy varies widely, ranging from 64% to 94%. Although methotrexate does not have significant risks, it can lead to life-threatening complications, including hospitalization and surgery in up to 29% of women receiving the therapy.
Overall, Bixby found that a patient's beta-HCG hormone rate offered the strongest predictor of methotrexate treatment failure. Although the success rate for all 62 patients was 76%, it fell to 50% in patients with beta-HCG values more than 2000, and to 20% in patients with values over 5000.
Nonetheless, the findings of yolk sac and heart motion with transvaginal ultrasound were the surest indications that single-dose methotrexate will not work. They should be listed as exclusion criteria in the procedure's clinical protocol, Bixby said.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can Intestinal Ultrasound Provide an Alternative for Evaluating Creeping Fat with Crohn’s Disease?
September 25th 2024Intestinal ultrasound demonstrated an 88.2 percent agreement with computed tomography enterography in characterizing creeping fat in patients with Crohn’s disease, according to new research.
FDA Clears Enhanced 3D Ultrasound Platform for Thyroid Imaging
September 23rd 2024The Piur tUS Infinity system reportedly reduces operator dependency with ultrasound through upgrading of two-dimensional ultrasound devices and access to 3D multiplanar image reconstructions of thyroid conditions.